In vitro safety pharmacology profiling: An important tool to decrease attrition

Hit and Lead Profiling: Identification and Optimization of Drug-like Molecules

Volumn 43, Issue , 2010, Pages 273-295

  Hamon, Jacques ^a   Whitebread, Steven ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

In vitro safety pharmacology profiling; Lead optimization; Secondary pharmacology profile

Indexed keywords

IN-VITRO; LEAD OPTIMIZATION; SAFETY PHARMACOLOGY; SECONDARY PHARMACOLOGY PROFILE;

EID: 85018193727     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527627448.ch12     Document Type: Chapter

References (61)

1. Kinter, L.B., Gossett, K.A. and Kerns,W.D. (1993) Status of safety pharmacology in the pharmaceutical industry, 1993. Drug Development Research, 32. (4), 208-216.
2. Kinter, L.D. and Dixon, L.W. (1995) Safety pharmacology program for pharmaceuticals. Drug Development Research, 35. (3), 179-182.
3. Sullivan, A.T. and Kinter, L.B. (1995) Status of safety pharmacology in the pharmaceutical industry-1995. Drug Development Research, 35. (3), 166-172.
4. Williams, P.D. (1990) The role of pharmacology profiling in safety assessment. Regulatory Toxicology and Pharmacology, 12. (3), 238-252.
5. U.S. Food and Drug Administration (2001) International conference on harmonisation, S7A Safety pharmacology studies for human pharmaceuticals. U.S. Food and Drug Administration, Washington.
6. Whitebread, S., Hamon, J., Bojanic, D. and Urban, L. (2005) In vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discovery Today, 10. (21), 1421-1433.
7. Vaz, R.J. and Klabunde, T. (eds) (2008) Antitargets, Wiley-VCH, Weinheim.
8. Wakefield, I.D., Pollard, C., Redfern,W.S., Hammond, T.G. and Valentin, J.P. (2002) The application of in vitro methods to safety pharmacology. Fundamental and Clinical Pharmacology, 16, 209-218.
9. Kinter, L.B. and Valentin, J.-P. (2002) Safety pharmacology and risk assessment. Fundamental and Clinical Pharmacology, 16, 175-182.
10. Schuster, D., Laggner, C. and Langer, T. (2005) Why drugs fail -A study on side effects in new chemical entities. Current Pharmaceutical Design, 11, 3545-3559.
11. Jooste, E., Klafter, F., Hirshman, C.A. and Emala, C.W. (2003) A mechanism for rapacuronium-induced bronchospasm: M2. muscarinic receptor antagonism. Anesthesiology, 98. (4), 906-911.
12. Morris, B.J., Cochran, S.M. and Pratt, J.A. (2005) PCP: from pharmacology to modelling schizophrenia. Current Opinion in Pharmacology, 5. (1), 101-106.
13. Gentili, F., Pizzinat, N., Ordener, C., Marchal-Victorion, S., Maurel, A., Hofmann, R., Renard, P., Delagrange, P. et al. (2006) 3-[5-(4,5-dihydro-1Himidazol-2-yl)-furan-2-yl]phenylamine (Amifuraline), a promising reversible and selective peripheral MAO-A inhibitor. Journal of Medicinal Chemistry, 49, 5578-5586.
14. McKenzie, R., Fried, M.W., Sallie, R., Conjeevaram, H., Di Bisceglie, A.M., Park, Y., Savarese, B., Kleiner, D. et al. (1995) Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. New England Journal of Medicine, 333, 1099-1105.
15. Lee, E.-W., Lai, Y., Zhang, H. and Unadkat, J.D. (2006) Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1. (hENT1): Implications for interspecies differences in mitochondrial toxicity of fialuridine. The Journal of Biological Chemistry, 281. (24), 16700-16706.
16. Kola, I. and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nature Reviews. Drug Discovery, 3, 711-715.
17. Lasser, K.E., Allen, P.D.,Woolhandler, S.J., Himmelstein, D.U., Wolfe, S.M. and Bor, D.H. (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA -Journal of the American Medical Association, 287. (17), 2215-2220.
18. Lazarou, J., Pomeranz, B.H. and Corey, P.N. (1998) Incidence of adverse drug reactions in hospitalized patients. JAMA -Journal of the AmericanMedical Association, 279, 1200-1205.
19. Hughes, B. (2008) FDA drug approvals: a year of flux. Nature Reviews. Drug Discovery, 7. (2), 107-109, http://dx.doi.org/ 10.1038/nrd2514.
20. Redfern, W.S., Wakefield, I.D., Prior, H., Pollard, C.E., Hammond, T.G. and Valentin, J.-P. (2002) Safety pharmacology -a progressive approach. Fundamental and Clinical Pharmacology, 16, 161-173.
21. Smith, D.A. and Schmid, E.F. (2006) Drug withdrawals and the lessons within. Current Opinion in Drug Discovery and Development, 9. (1), 38-46.
22. Spence, S., Anderson, C., Cukierski, M. and Patrick, D. (1999) Teratogenic effects of the endothelin receptor antagonist L-753,037. in the rat. Reproductive Toxicology, 13. (12), 15-29.
23. Niederreither, K. and Dolle, P. (2008) Retinoic acid in development: Towards an integrated view. Nature Reviews. Genetics, 9, 541-553.
24. Wishart, D.S., Knox, C., Guo, A.C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B. and Hassanali, M. (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets.NucleicAcids Research, 36, D901-D906.
25. United Nations (2005) Consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by governments. 12th issue. UN Office for Economic and Social Council Support and Coordination, pp. 595.
26. Wise, A., Gearing, K. and Rees, S. (2002) Target validation of G-protein coupled receptors. Drug Discovery Today, 7. (4), 235-246.
27. Fox, S., Farr-Jones, S., Sopchak, L., Boggs, A., Nicely, H.W., Khoury, R. and Biros, M. (2006) High-throughput screening: update on practices and success. Journal of Biomolecular Screening, 11. (7), 864-869.
28. Krejsa, C.M., Horvath, D., Rogalski, S.L., Penzotti, J.E., Mao, B., Barbosa, F. and Migeon, J.C. (2003) Predicting ADME properties and side effects: The BioPrint approach. Current Opinion in Drug Discovery and Development, 6. (4), 470-480.
29. Roth, B.L., Baner, K., Westkaemper, R., Siebert, D., Rice, K.C., Steinberg, S., Ernsberger, P. and Rothman, R.B. (2002) Salvinorin A: A potent naturally occurring nonnitrogenous k opioid selective agonist. Proceedings of the National Academy of Sciences of the United States of America, 99, 11934-11939.
30. Elphick, G.F., Querbes, W., Jordan, J.A., Gee, G.V., Eash, S.,Manley, K., Dugan, A., Stanifer, M. et al. (2004) The Human Polyomavirus, JCV Uses Serotonin Receptors to Infect Cells. Science, 306, 380-1383.
31. Silvestre, J.S. and Prous, J. (2005) Research on adverse drug events I. Muscarinic M3. receptor binding affinity could predict the risk of antipsychotics to induce type 2. diabetes. Methods and Findings in Experimental and Clinical Pharmacology, 27. (5), 289-304.
32. Yildirim, M.A., Goh, K.-I., Cusick, M.E., Barabasi, A.-L. and Vidal, M. (2007) Drug-target network. Nature Biotechnology, 25, 1119-1126.
33. Paolini, G.V., Shapland, R.H.B., Van Hoorn, W.P., Mason, J.S. and Hopkins, A.L. (2006) Global mapping of pharmacological space. Nature Biotechnology, 24, 805-815.
34. DeVane, C.L. and Nemeroff, C.B. (2001) An evaluation of risperidone drug interactions. Journal of Clinical Psychopharmacology, 21, 408-416.
35. Roth, B.L., Sheffler, D.J. and Kroeze, W.K. (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Reviews. Drug Discovery, 3, 353-359.
36. Youdim, M.B.H. (2006) The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and M30. Current Alzheimer Research, 3, 541-550.
37. Stephenson, V.C., Heydingb, R.A. and Weaver, D.F. (2005) The promiscuous drug concept? with applications to Alzheimers disease. FEBS letters, 579. (6), 1338-1342.
38. Hampton, T. (2004) Promiscuous? anticancer drugs that hit multiple targets may thwart resistance. The Journal of the American Medical Association, 292. (4), 419-422.
39. Rochon, P.A., Normand, S.-L., Gomes, T., Gill, S.S., Anderson, G.M., Melo, M., Sykora, K., Lipscombe, L., et al. (2008) Antipsychotic therapy and short-term serious events in older adults with dementia. Archives of Internal Medicine, 168. (10), 1090-1096.
40. Whitebread, S., Hamon, J., Scheiber, J., Fekete, A., Azzaoui, K., Mikhailov, D., Lu, Q. and Urban, L. (2008) Broad-scale in vitro pharmacology profiling to predict clinical adverse effects. American Drug Discovery, 3. (2), 32-38.
41. Hopkins, A.L.,Mason, J.S. and Overington, J.P. (2006) Can we rationally design promiscuous drugs? Current Opinion in Structural Biology, 16. (1), 127-136.
42. Aronov, A.M., McClain, B., Moody, C.S. and Murcko, M.A. (2008) Kinase-likeness and Kinase-Privileged Fragments: Toward Virtual Polypharmacology. Journal of Medicinal Chemistry, 51, 1214-1222.
43. Whitlock, G.A., Fish, P.V., Fray, M.J., Stobie, A. andWakenhut, F. (2008) Pyridylphenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity. Bioorganic and Medicinal Chemistry Letters, 18, 2896-2899.
44. Abe, C., Kikukawa, T. and Komatsu, Y. (1995) Combination therapy on murine arthritis -Salazosulfapyridine, bucillamine, and methotrexate. International Journal of Immunotherapy, 11, 129-132.
45. Burcoglu-O?Ral, A., Erkan, D. and Asherson, R. (2002) Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. Journal of Rheumatology, 29, 2006-2011.
46. Hamon, J., Azzaoui, K., Whitebread, S., Urban, L., Jacoby, E. and Faller, B. (2006) In vitro safety pharmacology profiling. European Pharmaceutical Review, 2006. (1), 60-63.
47. Azzaoui, K., Hamon, J., Faller, B., Whitebread, S., Jacoby, E., Bender, A., Jenkins, J.L. and Urban, L. (2007) Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem, 2, 874-880.
48. Leeson, P.D. and Springthorpe, B. (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nature Reviews. Drug Discovery, 6, 881-890.
49. Wilke, R.A., Lin, W., Roden, D.M., Watkins, P.B., Flockhart, D., Zineh, I., Giacomini, K.M. and Krauss, R.M. (2007) Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nature Reviews. Drug Discovery, 6, 904-916.
50. Redfern, W.S., Carlsson, L., Davis, A.S., Lynch,W.G.,MacKenzie, I., Palethorpe, S., Siegl, P.K.S., Strang, I. et al. (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovascular Research, 58, 32-45.
51. Ashburn, T.T. and Thor, K.B. (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nature Reviews. Drug Discovery, 3, 673-683.
52. O?Connor, K.A. and Roth, B.L. (2005) Finding new tricks for old drugs: An efficient route for public-sector drug discovery. Nature Reviews. Drug Discovery, 4, 1005-1014.
53. Verdonk, E., Johnson, K., McGuinness, R., Leung, G., Chen, Y.W., Tang, H.R., Michelotti, J.M. and Liu, V.F. (2006) Cellular dielectric spectroscopy: A label-free comprehensive platform for functional evaluation of endogenous receptors. Assay and Drug Development Technologies, 4. (5), 609-619.
54. Meyer, T., Sartipy, P., Blind, F., Leisgen, C. and Guenther, E. (2007) New cell models and assays in cardiac safety profiling. Expert Opinion on Drug Metabolism and Toxicology, 3. (4), 507-517.
55. Pouton, C.W. and Haynes, J.M. (2007) Embryonic stem cells as a source of models for drug discovery. Nature Reviews. Drug Discovery, 6. (8), 605-616.
56. Houck, K.A. and Kavlock, R.J. (2008) Understanding mechanisms of toxicity: insights from drug discovery research. Toxicology and Applied Pharmacology, 227. (2), 163-178.
57. Barros, T.P., Alderton, W.K., Reynolds, H.M., Roach, A.G. and Berghmans, S. (2008) Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. British Journal of Pharmacology, 154, 1400-1413.
58. Imming, P., Sinning, C. and Meyer, A. (2006) Drugs, their targets and the nature and number of drug targets. Nature Reviews. Drug Discovery, 5, 821-834.
59. Overington, J.P., Al-Lazikani, B. and Hopkins, A.L. (2006) How many drug targets are there? Nature Reviews. Drug Discovery, 5, 993-996.
60. Bender, A., Scheiber, J., Glick, M., Davies, J.W., Azzaoui, K., Hamon, J., Urban, L., Whitebread, S. and Jenkins, J.L. (2007) Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem, 2, 861-873.
61. Lamb, J., Crawford, E.D., Peck, D., Modell, J.W., Blat, I.C., Wrobel, M.J., Lerner, J., Brunet, J.-P. et al. (2006) The Connectivity Map: Using Gene-Expression Signatures to connect small molecules, genes, and disease. Science, 313, 1929-1935.